

Dextera Surgical Inc. (NASDAQ: DXTR), an innovative medical device company that develops and commercializes proprietary stapling devices enabling the advancement of minimally invasive surgical procedures, is dedicated to improving its products, distribution and supply chain. With increasing demand for minimally invasive surgery, Dextera's management team has designed a disruptive product in the MicroCutter 5/80™, the world's smallest profile articulating stapler. Moreover, management is now focused on building strategic partnerships that support the commercialization of its products while improving its supply chain to make it more efficient and cost effective.

Dextera's original product line, the C-Port® Distal and PAS-Port® Proximal Anastomosis Systems, are the only FDA-cleared automated anastomosis devices for coronary artery bypass graft (CABG) surgery available today. These products help enable less invasive CABG procedures, and the C-Port is an enabling technology for TECAB (totally endoscopic CABG). These products, sold by Dextera under the Cardica brand name, have demonstrated long-term reliable clinical performance for over thirteen years.

Company Highlights

Two proprietary, award-winning medical technology platforms advancing minimally invasive surgery:


MicroCutter

- Smallest diameter articulating surgical stapler
- \$2 billion total worldwide surgical stapling market
- 67 issued patents; CE Mark and 510(k) cleared
- Intuitive Surgical license & co-development agreement
- MicroCutter 5/80 commercial launch in Q1 CY2017 with \$500k sales
- B. Braun distribution in Spain & expansion plans for EU and OUS



PAS-Port & C-Port

- Only FDA-cleared proximal & distal automated anastomosis products for CABG
- Worldwide market 700k CABG procedures
- 67 issued patents; CE Mark and 510(k) clearances
- >63,000 PAS-Ports & C-Ports shipped to date
- Extensive clinical data for PAS-Port & C-Port
- Potential partnership with B. Braun for worldwide distribution



Near-Term Milestones

	3Q17	4Q17	1Q18	2Q18	3Q18	4Q18
Execute strategic partnership with B. Braun	████████████████████					
Supply chain optimization & production capacity growth	████████████████████					
Enrollment completed for MATCH Registry	████████████████████					
Expand MicroCutter indication to include liver in US	████████████████████					
Expand product pipeline	████████████████████					
Drive clinical adoption & revenue growth	████████████████████					
Deliver on Intuitive Surgical co-development project	████████████████████					

Nasdaq: DXTR

Financial Highlights

Market Cap: \$16M
 Shares Outstanding: 47.8M
 Cash as of 6/30/17: \$6M
 Fiscal 2017 Sales: \$3.4M

Management

Julian Nikolchev, President & CEO

Tom Palermo, COO

Bob Newell, CFO

Liam Burns, VP, Worldwide Sales & Marketing

Peggy McLaughlin, Consulting VP, Clinical Affairs

Brian A. Schar, General Counsel, Director of IP & Chief Compliance Officer

Pamela Segale, Consulting VP, Regulatory Affairs

Dr. Mark Soberman, Medical Director

Greg Watson, VP, Operations

Board of Directors

Michael A. Bates, Chairman, Independent Financial Executive, Angel Investor, Company Advisor

Thomas A. Afzal, President & CEO, Spinal Kinetics, Inc.

Gregory D. Casciaro, President, CEO & Director, Cardiac Dimensions, Inc.

R. Michael Kleine, Company Advisor, former President, CEO & Director, Miramar Labs, Inc.

Samuel E. Navarro, Managing Partner, Gravitass Healthcare, LLC

Julian Nikolchev, President & CEO, Dextera Surgical

Dextera Surgical Inc.

900 Saginaw Drive • Redwood City, CA 94063

Company Contact

Bob Newell • CFO
 (650) 331-7133
 investors@dexterasurgical.com

Investors Relations

Josh Berg • Berg Capital Markets
 (415) 205-7891
 josh@bergcapitalmarkets.com

MicroCutter 5/80™:

The World's Smallest Profile Articulating Surgical Stapler

- Dextera Surgical's MicroCutter 5/80™ surgical stapler is a breakthrough product for minimally invasive surgery
- Minimally invasive surgeries have been shown to reduce pain and recovery times for patients when compared to open procedures.¹ Instead of the larger incisions used during an open procedure, minimally invasive surgeries are performed through access ports. This requires special diameter tools including cameras, staplers, graspers and clips
- At 5mm in shaft diameter, MicroCutter is the smallest laparoscopic articulating stapler in the world – half the size of current staplers, and with 80 degrees of articulation, it articulates nearly twice as much as conventional staplers enabling the surgeon to reach and operate in small spaces
- With a much smaller footprint than traditional staplers and significant articulation, the MicroCutter 5/80 helps to enable minimally invasive surgeries. Minimally invasive surgeries are known to result in reduced trauma, less risk, less pain and shorter hospital stays
- In the U.S., surgical staplers are routinely used in more than one million minimally invasive laparoscopic, video-assisted or robotic-assisted surgical procedures annually. The market for surgical stapling tools worldwide is approximately \$2 billion

C-Port® Distal Anastomosis Systems (C-Port systems)

- Intended for use in the creation of anastomoses, or connections, in blood vessels and grafts, including use in coronary artery bypass grafting procedures
- Can be used on- or off-pump and create compliant anastomoses that expand and contract with blood flow
- Works on coronary arteries as small as 1.3 millimeters in internal diameter
- Works with grafts of various diameters and vessels with single wall thicknesses less than 0.75 millimeters
- Flex-A system allows surgeons to create a secure connection even in difficult to reach areas of the heart and enables TECAB (totally endoscopic CABG)
- Dextera has shipped over 15,300 C-Port systems worldwide since launch

PAS-Port® Proximal Anastomosis System (PAS-Port system)

- Intended to create the aortic anastomosis of aortic autologous vein grafts
- Fully-automated device used to perform an anastomosis between a saphenous vein and the aorta during either on- or off-pump CABG surgery
- Used in Japan and Europe since 2004
- Received 510(k) clearance in the United States in 2008
- Allows a surgeon to complete an automated connection of the bypass graft vessel to the aorta (known as a proximal anastomosis) without the need to clamp or manipulate the aorta. Less manipulation of the aorta may reduce the risk of stroke and other neurological complications
- Unique design allows for a comparable take-off angle when compared to hand-sewn sutures, and the PAS-Port's implant design does not introduce metal into the graft lumen
- Dextera has shipped over 47,600 PAS-Port systems since launch

Key Competitive Advantages


Smallest Surface Area

Up to 51% smaller surface area




Widest Articulation

Up to 78% greater articulation



Broadest Reach

At least 33% more reach



- Less Dissection
- Easier Placement
- Better Visibility
- Less Invasive

Enabling MIS procedure approaches that are "not possible with either the JustRight stapler or conventional staplers" (Pediatric Surgeon)

Commercialization Strategy



Strategic Partnerships



B. Braun Surgical S.A. Agreement

In Spain, Dextera entered into a marketing and distribution agreement with B. Braun Surgical S.A. whereby B. Braun Surgical S.A. will sell the MicroCutter 5/80 in Spain. B. Braun Surgical S.A. has an extensive network of direct and indirect sales representatives in Spain who focus on surgeons performing minimally invasive surgical procedures.



Intuitive Surgical Co-Development Agreement

Intuitive Surgical (NASDAQ:ISRG) first licensed Dextera's technology in August 2010. A 6-month evaluation in 2016 of the MicroCutter technology led to a co-development project for the stapling reload cartridge. Dextera has received \$11M in license fees and a \$3M equity investment from Intuitive Surgical for exclusive robotic rights to the MicroCutter technology. Dextera Surgical has an ongoing co-development project with Intuitive Surgical.

Please refer to package insert for indications, contraindications, warnings, precautions, and instructions for use.

1. Qiu, Chen, et al. "Sublobectomy versus Lobectomy for Stage I Non-Small Cell Lung Cancer in the Elderly." *International Journal of Surgery*, vol. 37, 2017, pp. 1-7., doi:10.1016/j.ijssu.2016.11.090.